A veteran of the pharma industry. Specializing in the analysis of small pharma companies with a focus on the pipeline and opportunities for licensing or major deals with large pharma. Financial analysis including burn rate, venture capital funding, and cash flow.
In the US, I am currently fully long: JNJ, UNP, CSCO, MSFT, ORCL, TROW, ADM and MGNA
In Germany, I am currently fully long: BASF, Munich Re and Henkel
In France, I am long ENGI
In the UK, I have full positions in BHP, RDSB, Unilever.
Entertainment Insight is your source of information about the entertainment industry. Here you'll find out the coverage of a wide variety of companies that create the future of your everyday life. From mobile developers and video gaming publishers to tech conglomerates and media empires. Find out more about the virtual or augmented reality devices that will shape your tommorow's thinking or have another look at the eSports arena and the opportunities it brings to the early investors. And also not to mention a number of relatively small companies or startups that are disrupting the traditional view of how you absorb your information by releasing apps or services that are helping you to achieve the best results out of what you have as fast as possible.
If you are interested in the entertainment industry and the opportunities that it brings to investors, then you should definitely follow Entertainment Insight.
If you have any questions about my articles or the industry, feel free to send me a direct message.
Hope you'll enjoy my coverage.
MD, MBA (NYU-Stern, Finance specialization). Founder: Vasuda Healthcare Analytics, premium research service covering emerging biotech/ pharma companies (in partnership with Seeking Alpha). Licensed Investment Advisor. Top-ranked analyst on Tipranks.
Insight Provider for Smartkarma Intelligent Investing (www.smartkarma.com): Institutional Investments Research Platform.
Buy-side equity research analyst covering mainly small-cap, emerging pharma/ biotech companies. M.D. with over 18 years of clinical experience (in the U.S. and India), still retaining full medical license in India. M.B.A. with finance and financial markets specialization from New York University Stern School of Business.
Expert in picking healthcare-related investments, especially biotechnology and pharmaceuticals (focus on small, emerging companies). Investments are selected based on detailed due diligence, including proprietary DCF valuation models. Value investor with long-term horizon.
Founder, managing principal of Vasuda Capital Management, healthcare focused investment management firm, vasudacapitalmanagement.com. Registered Investment Advisor in Massachusetts. The firm also operates a private investment partnership, Vasuda Life Sciences Fund.
Also started and continue to sponsor Vasuda Global Orphan/ Rare disease biotechnology index, the first global equity index covering rare/orphan disease sector. Index quotes are available on bloomberg/reuters terminals.
Over 30 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
I am an individual investor with 30 years of experience. Along with my trading experience I have a BS Bus, BS CMIS, MBA, passed CPA exam and leadership experience at 3 different Fortune 500 companies. I have also purchased, financed, built up and sold a small business.
I tend to follow about 50 companies across all industries and consider "Risk Management" to be my greatest strength. Through a combination of risk management and trading I was able to avoid and prosper from the recession.
My expectation is to beat the S&P 500 return and take less risk. I have accomplished that for several years in a row.
PhD Scientist with focus on biotechnology, specifically RNAi and miRNA.
I follow especially Arrowhead Pharmaceuticals (ARWR), Alnylam Pharmaceuticals (ALNY) and Regulus Therapeutics (RGLS). I consider RNA therapeutics to represent a promising new drug modality that could transform medicine.
Ian Bezek worked for 3 years as an analyst at a New York-based hedge fund. He's currently living in Mexico, pursuing some entrepreneurial opportunities.
Feel free to contact him regarding investments, writing, or speaking opportunities.
Just a Wayfaring Man working hard to separate the wheat from the chaff in the world of Wall Street. Presently trying learn some basic BioChem principles on the fly in order to maximize the opportunities and info abundantly available on SA.
Post-grad degree in Econ and Stats; qualifications, and long career, in computer programming and business analysis.
No special expertise in accounting or finance. Just another retail investor.
I am a financial adviser and Registered Investment Adviser specializing in emerging growth stocks. I am also a market technician with an article written in the Wall Street Journal about one of my market hedging techniques (Google: Moving The Market-Tracking The Numbers, Edward Levi, The Wall Street Journal). I've spent 11 years at Dean Witter, 18 at Smith Barney, and 8 at Morgan Stanley. I've decided to join Beverly Hills Wealth Management so that I can concentrate on building private hedge fund portfolios for clients, whether related to growth or income, or both.
I specialize in emerging growth investments that run the gamut from medical devices and therapies, technology, and alternative energy.
I've spent a lifetime of research in the technical aspects of the market, measuring market sentiment, momentum, and chart patterns. For many years I've given market presentations to financial advisers at Smith Barney and Morgan Stanley showing extremes in sentiment and chart patterns. I have my own proprietary indicators that measure extremes and hedge clients portfolios at times when protection is in order. My goal is to be fully invested in the rising trends but very protective of portfolios when sentiment and momentum indicators reach extremes. I'm usually early in predicting trends but usually right. Extreme sentiment is a leading indicator, and I believe it precludes market and economic fundamentals as a source of knowledge of changing trends.
I have been investing in stocks, bonds and real estate for about 40 years. My professional background is Analytical Chemistry (PhD, Purdue 1984) and I have worked in Pharmaceutical R&D (both Discovery and Development) for 30+ years. For the last 12+ of those years, I have been an intellectual-property and product-selection strategist for a major global pharmaceutical company. I believe in the Peter Lynch philosophy of investing in what you understand.
Motto: I invest in undervalued (i.e. cheap) well-established companies trading at a below market multiple.
The companies that I invest in are large stable companies with proven track records. My goal is the highest total return possible with the least amount of risk.
Professional Background: I am a healthcare practitioner with extensive experience in the pharmaceutical sector. I have a passion for investing honed over the past twenty years through various market cycles.
Executive Director of SPVInvestor Research, Inc.
I am evaluating solar companies based on their operational, financial
and growth factors. I can be found on our forum at
My professional background is in distribution, logistics, profit and loss management
within supply chain at the distribution level.